Liang Xinli, Chen Xulong, Zhao Guowei, Tang Tao, Dong Wei, Wang Chunyan, Zhang Jing, Liao Zhenggen
Key Laboratory of Modern Preparation of Traditional Chinese Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.
Pharmaceutics. 2018 Nov 16;10(4):236. doi: 10.3390/pharmaceutics10040236.
Imperatorin is a chemical compound belonging to the linear furanocoumarins. Imperatorin is attracting considerable attention because of its antitumor, antibacterial, anti-inflammatory, and anticoagulant activities, inhibition of myocardial hypertrophy, and other pharmacological efficacies. However, imperatorin has limited water solubility and has better lipid solubility; thus, we decided to design and synthesize imperatorin lipid microspheres to optimize the preparation conditions. The aim was to develop and formulate imperatorin lipid microspheres through nanoemulsion technology and apply the response surface⁻central composite design to optimize the imperatorin lipid microsphere formulation. The influence of the amounts of egg lecithin, poloxamer 188, and soybean oil for injection on the total percentage of the oil phase was investigated. The integrated effect of dependent variables, including particle size, polydispersity index, zeta potentials, drug loading, and encapsulation efficiency, was investigated. Data of overall desirabilities were fitted to a second-order polynomial equation, through which three-dimensional response surface graphs were described. Optimum experimental conditions were calculated by Design-Expert 8.06. Results indicated that the optimum preparation conditions were as follows: 1.39 g of egg lecithin, 0.21 g of poloxamer 188, and 10.57% soybean oil for injection. Preparation of imperatorin lipid microspheres according to the optimum experimental conditions resulted in an overall desirability of 0.7286, with the particle size of 168 ± 0.54 nm, polydispersity index (PDI) of 0.138 ± 0.02, zeta potentials of -43.5 ± 0.5 mV, drug loading of 0.833 ± 0.27 mg·mL, and encapsulation efficiency of 90 ± 1.27%. The difference between the observed and predicted values of the overall desirability of the optimum formulation was in the range from 2.4% to 4.3%. Subsequently, scanning electron microscopy was used to observe the micromorphology of the imperatorin lipid microspheres, showing round globules of relatively uniform shape and sizes within 200 nm. The effect of imperatorin lipid microspheres on MDA-MB-231 proliferation was investigated by the MTT method. Furthermore, pharmacokinetics in Sprague-Dawley rats was evaluated using orbital bleeding. A sensitive and reliable liquid chromatography with the high-performance liquid chromatography (HPLC) method was established and validated for the quantification of imperatorin in rat plasma samples. The data were calculated by DAS (drug and statistics) Pharmacokinetic Software version 3.3.0 (Version 3.3.0, Shanghai, China). Results demonstrated that imperatorin lipid microspheres can significantly enhance the bioavailability of imperatorin and can significantly inhibit MDA-MB-231 cell proliferation. In conclusion, our results suggested that the response surface⁻central composite design is suitable for achieving an optimized lipid microsphere formulation. Imperatorin lipid microspheres can improve the bioavailability of imperatorin and better inhibit the proliferation of MDA-MB-231 cells as compared to imperatorin alone.
欧前胡素是一种属于线性呋喃香豆素类的化合物。欧前胡素因其抗肿瘤、抗菌、抗炎、抗凝活性、抑制心肌肥大及其他药理功效而备受关注。然而,欧前胡素的水溶性有限,脂溶性较好;因此,我们决定设计并合成欧前胡素脂质微球以优化制备条件。目的是通过纳米乳技术研发并配制欧前胡素脂质微球,并应用响应面-中心复合设计来优化欧前胡素脂质微球的配方。研究了卵磷脂、泊洛沙姆188及注射用大豆油的用量对油相总百分比的影响。研究了包括粒径、多分散指数、ζ电位、载药量及包封率等因变量的综合效应。将综合可取性数据拟合为二阶多项式方程,据此绘制三维响应面图。通过Design-Expert 8.06计算最佳实验条件。结果表明,最佳制备条件如下:卵磷脂1.39 g、泊洛沙姆188 0.21 g及注射用大豆油10.57%。按照最佳实验条件制备欧前胡素脂质微球,综合可取性为0.7286,粒径为168±0.54 nm,多分散指数(PDI)为0.138±0.02,ζ电位为-43.5±0.5 mV,载药量为0.833±0.27 mg·mL,包封率为90±1.27%。最佳配方综合可取性的观测值与预测值之间的差异在2.4%至4.3%范围内。随后,使用扫描电子显微镜观察欧前胡素脂质微球的微观形态,显示形状相对均匀、尺寸在200 nm以内的圆形小球。采用MTT法研究欧前胡素脂质微球对MDA-MB-231细胞增殖的影响。此外,通过眶静脉取血评估了欧前胡素脂质微球在Sprague-Dawley大鼠体内的药代动力学。建立了一种灵敏可靠的高效液相色谱(HPLC)法,并经验证用于定量大鼠血浆样品中的欧前胡素。数据通过DAS(药物与统计学)药代动力学软件3.3.0版(版本3.3.0,中国上海)进行计算。结果表明,欧前胡素脂质微球可显著提高欧前胡素的生物利用度,并能显著抑制MDA-MB-231细胞增殖。总之,我们的结果表明响应面-中心复合设计适用于实现脂质微球配方的优化。与单独使用欧前胡素相比,欧前胡素脂质微球可提高欧前胡素的生物利用度,并能更好地抑制MDA-MB-231细胞的增殖。